Advanced Science (Feb 2022)
Patient‐Derived Upper Tract Urothelial Carcinoma Organoids as a Platform for Drug Screening
- Zhichao Li,
- Haibo Xu,
- Yanqing Gong,
- Wei Chen,
- Yonghao Zhan,
- Lei Yu,
- Yangyang Sun,
- Aolin Li,
- Shiming He,
- Bao Guan,
- Yucai Wu,
- Gengyan Xiong,
- Dong Fang,
- Yuhui He,
- Qi Tang,
- Lin Yao,
- Zheng Hu,
- Hongbing Mei,
- Zhisong He,
- Zhiming Cai,
- Yinglu Guo,
- Xuesong Li,
- Liqun Zhou,
- Weiren Huang
Affiliations
- Zhichao Li
- Department of Urology Peking University First Hospital National Urological Cancer Center Beijing 100034 China
- Haibo Xu
- Department of Urology Shenzhen Institute of Translational Medicine Shenzhen Second People's Hospital The First Affiliated Hospital of Shenzhen University International Cancer Center of Shenzhen University Shenzhen 518039 China
- Yanqing Gong
- Department of Urology Peking University First Hospital National Urological Cancer Center Beijing 100034 China
- Wei Chen
- Department of Urology Shenzhen Institute of Translational Medicine Shenzhen Second People's Hospital The First Affiliated Hospital of Shenzhen University International Cancer Center of Shenzhen University Shenzhen 518039 China
- Yonghao Zhan
- Department of Urology Peking University First Hospital National Urological Cancer Center Beijing 100034 China
- Lei Yu
- Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors Shenzhen 518035 China
- Yangyang Sun
- Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors Shenzhen 518035 China
- Aolin Li
- Department of Urology Peking University First Hospital National Urological Cancer Center Beijing 100034 China
- Shiming He
- Department of Urology Peking University First Hospital National Urological Cancer Center Beijing 100034 China
- Bao Guan
- Department of Urology Peking University First Hospital National Urological Cancer Center Beijing 100034 China
- Yucai Wu
- Department of Urology Peking University First Hospital National Urological Cancer Center Beijing 100034 China
- Gengyan Xiong
- Department of Urology Peking University First Hospital National Urological Cancer Center Beijing 100034 China
- Dong Fang
- Department of Urology Peking University First Hospital National Urological Cancer Center Beijing 100034 China
- Yuhui He
- Department of Urology Peking University First Hospital National Urological Cancer Center Beijing 100034 China
- Qi Tang
- Department of Urology Peking University First Hospital National Urological Cancer Center Beijing 100034 China
- Lin Yao
- Department of Urology Peking University First Hospital National Urological Cancer Center Beijing 100034 China
- Zheng Hu
- Shenzhen Institute of Synthetic Biology Shenzhen Institutes of Advanced Technology Chinese Academy of Sciences Shenzhen 518055 China
- Hongbing Mei
- Department of Urology Shenzhen Institute of Translational Medicine Shenzhen Second People's Hospital The First Affiliated Hospital of Shenzhen University International Cancer Center of Shenzhen University Shenzhen 518039 China
- Zhisong He
- Department of Urology Peking University First Hospital National Urological Cancer Center Beijing 100034 China
- Zhiming Cai
- Department of Urology Shenzhen Institute of Translational Medicine Shenzhen Second People's Hospital The First Affiliated Hospital of Shenzhen University International Cancer Center of Shenzhen University Shenzhen 518039 China
- Yinglu Guo
- Department of Urology Peking University First Hospital National Urological Cancer Center Beijing 100034 China
- Xuesong Li
- Department of Urology Peking University First Hospital National Urological Cancer Center Beijing 100034 China
- Liqun Zhou
- Department of Urology Peking University First Hospital National Urological Cancer Center Beijing 100034 China
- Weiren Huang
- Department of Urology Peking University First Hospital National Urological Cancer Center Beijing 100034 China
- DOI
- https://doi.org/10.1002/advs.202103999
- Journal volume & issue
-
Vol. 9,
no. 4
pp. n/a – n/a
Abstract
Abstract Upper tract urothelial carcinomas (UTUCs) are rare entities that are usually diagnosed at advanced stages. Research on UTUC pathobiology and clinical management has been hampered by the lack of models accurately reflecting disease nature and diversity. In this study, a modified organoid culture system is used to generate a library of 25 patient‐derived UTUC organoid lines retaining the histological architectures, marker gene expressions, genomic landscapes, and gene expression profiles of their parental tumors. The study demonstrates that the responses of UTUC organoids to anticancer drugs can be identified and the model supports the exploration of novel treatment strategies. This work proposes a modified protocol for generating patient‐derived UTUC organoid lines that may help elucidate UTUC pathophysiology and assess the responses of these diseases to various drug therapies in personalized medicine.
Keywords
